Mohammad-Nazir Menbari1, Karim Rahimi2,3, Abbas Ahmadi1, Samira Mohammadi-Yegane4,5, Anvar Elyasi6, Nikoo Darvishi1, Vahedeh Hosseini1, Mohammad Abdi1,7. 1. Cellular and Molecular Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences, Sanandaj, Iran. 2. Department of Molecular Biology and Genetics, Gene Expression and Gene Medicine, Aarhus University, Aarhus, Denmark. 3. Interdisciplinary Nanoscience Center, Aarhus University, Aarhus, Denmark. 4. Medical Nanotechnology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 5. Department of Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 6. Department of Surgery, Faculty of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran. 7. Department of Clinical Biochemistry, Faculty of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran.
Abstract
Background: Previous data have shown the tumorigenicity roles of histone deacetylase 8 (HDAC 8) in breast cancer. More recently, the oncogenic effects of this molecule have been revealed in triple negative breast cancer (TNBC). The present study aimed to determine the diagnostic value of HDAC8 for the differentiation of TNBC from nTNBC tumors. Methods: A total of 50 cancerous and normal adjacent tumor specimens were obtained, and the clinical and pathological findings of studied subjects were recorded. The expression of HDAC8 gene was determined by qRT-PCR. Also, immunohistochemical staining was performed on tissue samples. Results: Our results showed that the expression of HDAC8 in breast cancer tissues was significantly higher than the normal adjacent tissues (p = 0.0011). HDAC8 expression was also observed to be higher in TNBC patients than nTNBC group (p = 0.0013). In addition, in the TNBC group, there was a significant association between the HDAC8 overexpression and tumor characteristics, including tumor size (p = 0.039), lymphatic invasion (p = 0.01), tumor grade (p = 0.02), and perineural invasion (p < 0.05). The cut-off value was fixed at 0.6279 r.u., and the corresponding sensitivity and specificity were found to be 73.91% and 70.37%, respectively. Conclusion: According to the findings, among the other markers, HDAC8 oncogene may be used as a potential tumor marker in the diagnosis of TNBC tumors.
Background: Previous data have shown the tumorigenicity roles of histone deacetylase 8 (HDAC 8) in breast cancer. More recently, the oncogenic effects of this molecule have been revealed in triple negative breast cancer (TNBC). The present study aimed to determine the diagnostic value of HDAC8 for the differentiation of TNBC from nTNBC tumors. Methods: A total of 50 cancerous and normal adjacent tumor specimens were obtained, and the clinical and pathological findings of studied subjects were recorded. The expression of HDAC8 gene was determined by qRT-PCR. Also, immunohistochemical staining was performed on tissue samples. Results: Our results showed that the expression of HDAC8 in breast cancer tissues was significantly higher than the normal adjacent tissues (p = 0.0011). HDAC8 expression was also observed to be higher in TNBCpatients than nTNBC group (p = 0.0013). In addition, in the TNBC group, there was a significant association between the HDAC8 overexpression and tumor characteristics, including tumor size (p = 0.039), lymphatic invasion (p = 0.01), tumor grade (p = 0.02), and perineural invasion (p < 0.05). The cut-off value was fixed at 0.6279 r.u., and the corresponding sensitivity and specificity were found to be 73.91% and 70.37%, respectively. Conclusion: According to the findings, among the other markers, HDAC8 oncogene may be used as a potential tumor marker in the diagnosis of TNBC tumors.
Entities:
Keywords:
Breast cancer; HDAC8; Triple negative breast cancer
Authors: Zhao-Tong Wang; Zhuo-Jia Chen; Guan-Min Jiang; Ying-Min Wu; Tao Liu; Yan-Mei Yi; Jun Zeng; Jun Du; Hong-Sheng Wang Journal: Cell Signal Date: 2016-02-11 Impact factor: 4.315
Authors: J M Ruijter; C Ramakers; W M H Hoogaars; Y Karlen; O Bakker; M J B van den Hoff; A F M Moorman Journal: Nucleic Acids Res Date: 2009-02-22 Impact factor: 16.971